KR20190009343A - 에테플리센을 포함하는 약제학적 조성물 - Google Patents

에테플리센을 포함하는 약제학적 조성물 Download PDF

Info

Publication number
KR20190009343A
KR20190009343A KR1020187036635A KR20187036635A KR20190009343A KR 20190009343 A KR20190009343 A KR 20190009343A KR 1020187036635 A KR1020187036635 A KR 1020187036635A KR 20187036635 A KR20187036635 A KR 20187036635A KR 20190009343 A KR20190009343 A KR 20190009343A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
potassium
another embodiment
chloride
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187036635A
Other languages
English (en)
Korean (ko)
Inventor
토마스 홀트
Original Assignee
사렙타 쎄러퓨틱스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사렙타 쎄러퓨틱스 인코퍼레이티드 filed Critical 사렙타 쎄러퓨틱스 인코퍼레이티드
Publication of KR20190009343A publication Critical patent/KR20190009343A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020187036635A 2016-05-24 2017-05-24 에테플리센을 포함하는 약제학적 조성물 Ceased KR20190009343A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662340947P 2016-05-24 2016-05-24
US62/340,947 2016-05-24
US201662429160P 2016-12-02 2016-12-02
US62/429,160 2016-12-02
PCT/US2017/034265 WO2017213854A1 (en) 2016-05-24 2017-05-24 Pharmaceutical composition comprising eteplirsen

Publications (1)

Publication Number Publication Date
KR20190009343A true KR20190009343A (ko) 2019-01-28

Family

ID=59093599

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187036635A Ceased KR20190009343A (ko) 2016-05-24 2017-05-24 에테플리센을 포함하는 약제학적 조성물

Country Status (15)

Country Link
US (1) US20190275072A1 (https=)
EP (1) EP3463390A1 (https=)
JP (1) JP2019516730A (https=)
KR (1) KR20190009343A (https=)
CN (1) CN109562123A (https=)
AU (1) AU2017278699A1 (https=)
BR (1) BR112018074299A2 (https=)
CA (1) CA3024178A1 (https=)
CO (1) CO2018013828A2 (https=)
IL (1) IL263040A (https=)
MA (1) MA45158A (https=)
MX (1) MX2018014129A (https=)
SG (1) SG11201809494VA (https=)
TW (1) TW201805002A (https=)
WO (1) WO2017213854A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
EP3806868A4 (en) * 2018-06-13 2022-06-22 Sarepta Therapeutics, Inc. EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
WO2019241385A2 (en) * 2018-06-13 2019-12-19 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystropy
JP7579147B2 (ja) * 2018-06-14 2024-11-07 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート
EP4671372A3 (en) 2024-01-29 2026-03-11 Arnatar Therapeutics, Inc Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
WO1986005519A1 (en) 1985-03-15 1986-09-25 James Summerton Polynucleotide assay reagent and method
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
WO1990002749A1 (en) 1988-09-01 1990-03-22 Forskningscenter Risø Peptide synthesis method and solid support for use in the method
EP2933332A1 (en) 2004-06-28 2015-10-21 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
RU2606627C2 (ru) 2007-11-15 2017-01-10 Серепта Терапьютикс,Инк. Способ синтеза морфолиновых олигомеров
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
ES2607603T3 (es) 2010-09-30 2017-04-03 Nippon Shinyaku Co., Ltd. Derivado de ácido morfolino nucleico
JP6496549B2 (ja) 2011-11-30 2019-04-03 サレプタ セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症における誘発されたエクソン包含
CN103933549A (zh) * 2013-01-17 2014-07-23 刘海俊 一种新的血管抑素滴眼剂及其制备方法
US20140329762A1 (en) * 2013-03-15 2014-11-06 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy

Also Published As

Publication number Publication date
MA45158A (fr) 2019-04-10
US20190275072A1 (en) 2019-09-12
MX2018014129A (es) 2019-04-29
TW201805002A (zh) 2018-02-16
BR112018074299A2 (pt) 2019-03-12
WO2017213854A1 (en) 2017-12-14
CA3024178A1 (en) 2017-12-14
EP3463390A1 (en) 2019-04-10
SG11201809494VA (en) 2018-12-28
IL263040A (en) 2018-12-31
AU2017278699A1 (en) 2018-11-15
CO2018013828A2 (es) 2018-12-28
CN109562123A (zh) 2019-04-02
JP2019516730A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
US20230348524A1 (en) Technologies for oligonucleotide preparation
KR20190009343A (ko) 에테플리센을 포함하는 약제학적 조성물
US11384105B2 (en) Processes for preparing oligomers
KR20190013844A (ko) 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법
CN111655849A (zh) 一种核酸、含有该核酸的药物组合物和缀合物及其用途
JP2020528910A5 (https=)
WO2012075117A2 (en) Small molecule-polymer conjugates and methods of making same
WO2022222986A1 (en) Cyclic peptide-n-acetylgalactosamine (galnac) conjugates for drug delivery to liver cells
JP2020528910A (ja) オリゴヌクレオチド化合物の調製方法
JP2020535141A (ja) 高速流動合成を介してホスホロジアミデートモルホリノオリゴマーを調製するための方法
KR20190017805A (ko) 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법
WO2021025899A1 (en) Phosphorodiamidate morpholino oligomer pharmaceutical compositions
CN115944597B (zh) 硫代寡核苷酸注射剂及其制备方法
WO2026007243A1 (zh) 一种用于治疗乙肝的双靶点双链rna及药物组合物
HK40016300A (en) Processes for preparing phosphorodiamidate morpholino oligomers
HK40029120A (en) Sirna conjugate, preparation method therefor and use thereof
HK40029116A (en) Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
HK40019837B (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
HK40005805A (en) Processes for preparing oligomers
BR122024017733A2 (pt) Compostos oligômeros morfolino fosforodiamidato e processos para preparar os mesmos

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181217

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200522

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220513

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220817

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220513

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I